Hinova Pharmaceuticals, a Chinese drugmaker that focuses on the treatment of cancer and metabolic disorders, has completed a 1.063-billion-yuan ($166.9 billion) initial public offering (IPO) on Shanghai’s Nasdaq-style STAR Market on Tuesday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
